B of A Securities Maintains Underperform on TG Therapeutics, Raises Price Target to $20
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains TG Therapeutics (NASDAQ:TGTX) with a Underperform and raises the price target from $17 to $20.
B of A Securities analyst Alec Stranahan maintains TG Therapeutics (NASDAQ:TGTX) with a Underperform and raises the price target from $17 to $20.